Continuous Preparative SEC for Purification of "Difficult-to-Manufacture" Proteins-A Feasibility Study.

The advent of new antibody formats, such as multispecific antibodies or Fc-fusion proteins, imposes new challenges on downstream processing. Classical Protein A or ion exchange chromatography may not be capable of delivering adequate product quality if impurities display similar physicochemical prop...

Descripción completa

Detalles Bibliográficos
Publicado en:BioPharm International Vol. 33; no. 11; pp. 28 - 35
Autores principales: BRAND, KILIAN, CAPITO, FLORIAN, OEINCK, VERENA, FLATO, HENDRIK, BISSCHOPS, MARC, GLENZ, MARTIN, EHRET, RALF
Formato: Journal Article
Publicado: MJH Life Sciences Nov2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146958938&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 146958938
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1542166X
        5NE
      jtl: BioPharm International
      issn: 1542166X
      maglogo: N
    pubinfo:
      dt: Nov2020
      vid: 33
      iid: 11
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        146958938
        146958938
      ppf: 28
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Continuous Preparative SEC for Purification of "Difficult-to-Manufacture" Proteins-A Feasibility Study.
      aug:
        au:
          BRAND, KILIAN
          CAPITO, FLORIAN
          OEINCK, VERENA
          FLATO, HENDRIK
          BISSCHOPS, MARC
          GLENZ, MARTIN
          EHRET, RALF
        affil: Lab technician downstream process development, Sanofi-Aventis Deutschland GmbH
      sug:
      ab: The advent of new antibody formats, such as multispecific antibodies or Fc-fusion proteins, imposes new challenges on downstream processing. Classical Protein A or ion exchange chromatography may not be capable of delivering adequate product quality if impurities display similar physicochemical properties compared to the target product. Size exclusion chromatography (SEC) with the possibility to purify according to the molecule size suffers from low productivity and is, thus, rarely used in commercial antibody purification. In this feasibility study, the principle suitability of continuous SEC using simulated moving bed chromatography to separate bovine serum albumin (BSA) and myoglobin, as model proteins, is shown. The applicability of this approach for separation of high molecular weight species (HMWs) from a multispecific antibody is then further evaluated. Compared to batch SEC, productivity is increased by a factor of 2.2 while maintaining higher product quality and yield. Additionally, BSA and myoglobin are separated with a productivity increase of factor 3.3-3.4, showing the feasibility of considering continuous SEC as an emerging viable option for "difficult-to-manufacture" proteins, especially for purification of a specific molecule in larger quantities.
      pubtype: Trade Publication
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N